Sangril DS900 mg+100 mg

Sangril DS is a micronized purified flavonoid combination (a venotonic / vascular-protective agent) used for the following indications:

Established / commonly approved uses

• Chronic venous insufficiency (CVI): Symptomatic treatment of symptoms related to venous-lymphatic insufficiency such as leg heaviness, pain, nocturnal cramps, and edema (swelling) of the lower limbs.
• Hemorrhoidal disease: Symptomatic treatment of the functional signs of acute hemorrhoidal attacks (pain, bleeding, discomfort) and as an adjunct in the management of chronic hemorrhoidal symptoms.

Notes on evidence and scope

• Sangril DS treats the symptoms of venous insufficiency and hemorrhoids; it does not correct underlying structural venous disease (e.g., significant varicose veins), which may require compression therapy, sclerotherapy, or surgical management.
• It does not replace medical evaluation of hemorrhoidal symptoms if bleeding is significant, persistent, or accompanied by other concerning features (e.g., weight loss, change in bowel habit), which require assessment to exclude other causes.
• Some venous leg ulcer protocols use it as an adjunct to standard compression therapy, based on limited supportive evidence; it is not a substitute for standard ulcer care.

Each tablet typically contains a micronized purified flavonoid fraction consisting of Diosmin + Hesperidin in a fixed ratio (commonly diosmin 90% and hesperidin 10%, e.g. diosmin 450 mg + hesperidin 50 mg per 500 mg tablet). Exact strengths vary by brand and market; always check the specific product label.

Sangril DS is a fixed-dose combination of two citrus-derived flavonoids belonging to the "venotonic" or vasoprotective drug class. It is formulated as a micronized preparation to improve gastrointestinal absorption. Sangril DS is widely used for the symptomatic relief of chronic venous insufficiency of the lower limbs and for acute and chronic hemorrhoidal disease.

Venotonic / vasoprotective agent (flavonoid combination) — Sangril DS belongs to the class of drugs used for venous and capillary insufficiency and hemorrhoidal disease.

Mechanism

Diosmin + Hesperidin acts on the venous system and microcirculation through several complementary effects:

• Increased venous tone: Prolongs the vasoconstrictive effect of noradrenaline on the venous wall, reducing venous distensibility and capacitance, and decreasing venous stasis.
• Improved lymphatic drainage: Increases lymphatic flow rate and lymphatic capillary resorption, reducing edema.
• Microcirculatory protection: Reduces capillary hyperpermeability and increases capillary resistance.
• Anti-inflammatory action: Reduces leukocyte adhesion and migration at the level of the venous wall and inhibits release of inflammatory mediators, which is thought to contribute to its effect in acute hemorrhoidal attacks.

Pharmacokinetics

The micronized formulation of Diosmin + Hesperidin improves oral bioavailability compared with non-micronized forms. Diosmin is largely metabolized to its aglycone diosmetin and other flavonoid metabolites in the gut before absorption; elimination occurs mainly via feces and, to a lesser extent, urine.

Sangril DS tablets should be taken orally, swallowed whole with a glass of water, preferably with meals to reduce the chance of gastrointestinal discomfort. Do not crush or chew unless the product label specifically allows it.

No major, well-established clinically significant drug-drug interactions have been documented for Sangril DS at recommended doses. As with other flavonoid-containing products, theoretical additive effects with other agents affecting the vasculature are possible but not clinically established. Patients should inform their physician of all other medicines, supplements, and herbal products they are taking before starting Sangril DS.

Sangril DS is generally well tolerated at recommended doses. Reported adverse effects include:

• Common: Mild gastrointestinal disturbances — diarrhea, dyspepsia, nausea, vomiting.
• Uncommon: Headache, dizziness, malaise.
• Rare: Skin rash, pruritus, urticaria, isolated reports of colitis.

Patients should seek medical attention if a hypersensitivity reaction (e.g., facial/lip/throat swelling, severe rash, difficulty breathing) occurs while taking Sangril DS.

Data on the use of Sangril DS in pregnancy are limited. As a general precaution, Sangril DS should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; use should be under medical supervision. Similarly, because it is not established whether the components of Sangril DS pass into breast milk in clinically significant amounts, caution is advised during breastfeeding and a physician should be consulted before use. Do not self-medicate with Sangril DS during pregnancy or lactation without medical advice.

• Sangril DS is intended for symptomatic relief; if symptoms of hemorrhoidal disease do not improve within a few days, or if rectal bleeding is significant, persistent, or recurrent, stop self-treatment and seek prompt medical evaluation to exclude other causes.
• Sangril DS does not treat the underlying structural cause of chronic venous insufficiency (e.g., significant varicose veins); patients with significant venous disease should be evaluated for compression therapy or other definitive management alongside Sangril DS.
• See Contraindications for hypersensitivity information and Pregnancy and Lactation for use during pregnancy/breastfeeding.
• Use with caution in patients with a history of gastrointestinal sensitivity, as mild GI upset can occur (see Side Effects).

Limited data exist on overdose with Sangril DS; it has a wide margin of safety at recommended doses. In case of suspected overdose, symptoms would most likely be an exaggeration of known gastrointestinal side effects. There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Safety and efficacy of Sangril DS in children have not been well established; it is generally not recommended for use in the pediatric population outside specific physician guidance.

Elderly

No specific dose adjustment is generally required in elderly patients, but Sangril DS should be used with the same precautions as in adults, with attention to any comorbid conditions.

Renal/hepatic impairment

Specific dose-adjustment data for Sangril DS in renal or hepatic impairment are not well established; use with caution and under medical supervision in these populations.

For chronic venous insufficiency, Sangril DS is typically used as a longer-term or intermittent course as advised by the physician, since symptoms may recur if treatment is stopped. For acute hemorrhoidal attacks, a short course of about 7 days (with an initial higher dose tapered to maintenance, as above) is typical. Duration should be individualized by the prescribing physician.

Flavonoids; venotonics; vasoprotective agents — Diosmin + Hesperidin is classified within this drug class.

Diosmin + Hesperidin increases venous tone and lymphatic drainage, reduces capillary hyperpermeability, and exerts anti-inflammatory effects on the venous wall by reducing leukocyte-endothelial interaction — collectively improving symptoms of venous insufficiency and hemorrhoidal disease. See Pharmacology for details.

Sangril DS is not well established for use in children; safety and efficacy data in the pediatric population are lacking. It should generally not be used in children unless specifically directed by a physician.